Syringocystadenoma papilliferum

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:840D23.9
Who is this for?
Show terms as
3Active trials2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Syringocystadenoma papilliferum (SCAP) is a rare, benign (non-cancerous) skin tumor that develops from sweat gland tissue. It is sometimes called a sweat gland hamartoma or papillary syringocystadenoma. This condition most often appears on the scalp or face, though it can also develop on the neck, trunk, or other areas of the body. The tumor usually looks like a warty, raised, or crusted skin growth that may ooze or feel moist to the touch. It is often present at birth or appears during early childhood, sometimes growing more noticeable around puberty. Syringocystadenoma papilliferum is frequently found alongside another skin condition called nevus sebaceus, which is a yellowish, hairless patch of skin that is present from birth. When these two conditions occur together, the SCAP growth often develops within the nevus sebaceus area during childhood or adolescence. While SCAP itself is almost always benign, there is a small chance that it can be associated with other skin tumors over time, so regular monitoring by a skin specialist is important. The main treatment for syringocystadenoma papilliferum is surgical removal of the growth. Most people who have the tumor removed do very well and do not experience recurrence. Because this is a skin condition and not a systemic disease, it generally does not affect internal organs or overall health. Early diagnosis and appropriate management by a dermatologist or skin surgeon can lead to excellent outcomes for most patients.

Also known as:

Key symptoms:

Warty or bumpy raised skin growth, usually on the scalp or faceMoist or oozing surface on the skin lesionCrusting or scabbing on the growthHairless patch of skin where the tumor developsSkin growth that may enlarge around pubertyReddish or skin-colored nodule or plaqueItching or mild discomfort around the lesionGrowth appearing within a yellowish hairless birthmark (nevus sebaceus)

Clinical phenotype terms (5)— hover any for plain English
Nevus sebaceousHP:0010815
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

6 events
Feb 2026Epidemiology and Current Practices in Severe Community-Acquired Pneumonia

Universidad de la Sabana

TrialNOT YET RECRUITING
Sep 2025Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)

Qingyuan Zhan — PHASE2, PHASE3

TrialNOT YET RECRUITING
Jun 2025Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea

CHOSEOK YOON — NA

TrialNOT YET RECRUITING
May 2025ESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly PatientsAcquired Pneumonia (sCAP) in Elderly Patients"

Joan Sabater Riera

TrialENROLLING BY INVITATION
Jan 2025Determination of Scapulothoracic and Glenohumeral Angles by Imaging in Patients After Shoulder Arthroplasty (SCAP-imag)

Ramsay Générale de Santé — NA

TrialRECRUITING
Sep 2023Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

Biotest — PHASE3

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Syringocystadenoma papilliferum.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 31 trial
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Phase 3
Actively Recruiting
PI: Ricard Ferrer Roca, Dr. (Hospital Vall d'Hebron) · Sites: Mobile, Alabama; Fresno, California +144 more · Age: 1899 yrs
N/A1 trial
Determination of Scapulothoracic and Glenohumeral Angles by Imaging in Patients After Shoulder Arthroplasty (SCAP-imag)
N/A
Actively Recruiting
· Sites: Lyon · Age: 1899 yrs
Other1 trial
ESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly PatientsAcquired Pneumonia (sCAP) in Elderly Patients"
Enrolling by Invitation
PI: Jordi Rello, phD, MD (European Study Group Infections in the Elderly. ES) · Sites: Zagreb, City of Zagreb; Alès +16 more · Age: 6599 yrs

Specialists

2 foundView all specialists →
LR
Luis Felipe Reyes
Specialist
PI on 1 active trial
AD
Adrian Egli, PD Dr.
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Syringocystadenoma papilliferum.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Syringocystadenoma papilliferumForum →

No community posts yet. Be the first to share your experience with Syringocystadenoma papilliferum.

Start the conversation →

Latest news about Syringocystadenoma papilliferum

Disease timeline:

New recruiting trial: Determination of Scapulothoracic and Glenohumeral Angles by Imaging in Patients After Shoulder Arthroplasty (SCAP-imag)

A new clinical trial is recruiting patients for Syringocystadenoma papilliferum

New recruiting trial: Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

A new clinical trial is recruiting patients for Syringocystadenoma papilliferum

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Should this growth be removed, and if so, what is the best timing for surgery?,Is this growth related to a nevus sebaceus, and does that change the treatment plan?,What is the risk that this lesion could become cancerous if left untreated?,What type of surgery is recommended, and will it leave a scar?,How often should my child have skin check-ups after treatment?,Are there any signs I should watch for that would mean I need to come back sooner?,Does my child need any other tests to check for related skin conditions?

Common questions about Syringocystadenoma papilliferum

What is Syringocystadenoma papilliferum?

Syringocystadenoma papilliferum (SCAP) is a rare, benign (non-cancerous) skin tumor that develops from sweat gland tissue. It is sometimes called a sweat gland hamartoma or papillary syringocystadenoma. This condition most often appears on the scalp or face, though it can also develop on the neck, trunk, or other areas of the body. The tumor usually looks like a warty, raised, or crusted skin growth that may ooze or feel moist to the touch. It is often present at birth or appears during early childhood, sometimes growing more noticeable around puberty. Syringocystadenoma papilliferum is frequ

How is Syringocystadenoma papilliferum inherited?

Syringocystadenoma papilliferum follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Syringocystadenoma papilliferum?

Yes — 3 recruiting clinical trials are currently listed for Syringocystadenoma papilliferum on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Syringocystadenoma papilliferum?

2 specialists and care centers treating Syringocystadenoma papilliferum are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.